BFRG

Bullfrog AI Holdings, Inc. is a technology-enabled drug development company. The Company is focused specifically on advanced artificial intelligence/machine learning (AI/ML) analysis of complex data in the advancement of medicine. The Company’s platform technology, bfLEAP, is an analytical AI/ML platform that is a potentially disruptive tool for the analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational research and development and clinical trial settings. The platform can capture the genetic and physical characteristics of patients in an unbiased manner and contextualize them against other disparate data sources from patients. Its siRNA targets Beta2-spectrin in the treatment of human diseases, such as hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Mebendazole is focused on targeting Glioblastoma.

Wall Street analysts forecast BFRG stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BFRG is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Bullfrog AI Holdings Inc revenue for the last quarter amounts to 83.41K USD, decreased % YoY.

Bullfrog AI Holdings Inc. EPS for the last quarter amounts to -0.15 USD, decreased -31.82 % YoY.

Bullfrog AI Holdings Inc (BFRG) has 9 emplpoyees as of December 15 2025.

Today BFRG has the market capitalization of 12.55M USD.